ILIAD-7
Recombinant InterLeukin-7 (CYT107) to improve clinical outcomes in lymphopenic patients with COVID-19 infection
Type: Interventional
Site and lead:
- Wythenshawe Hospital: Dr Tim Felton
Patient group: All COVID-19 patients
Intervention:
- IL-7 (CYT107)
Funder: RevImmune
Sponsor: RevImmune
- ILIAD-7 is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.
